ResearcherStony Brook UniversityActive in the last 2 years
Ryan R. Kawalerski
Matched on ORCID iD 0000-0002-5518-8210; OpenAlex author ID A5051759283; NIH RePORTER profile ID 16083071. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 17
2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 grant
Papers 5
- Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. First author DOI 10.1038/s42003-023-04461-6↗
- Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases Co-author DOI 10.1101/2022.08.27.504988↗
- Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Co-author DOI 10.18632/oncotarget.27901↗
- An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Co-author DOI 10.1002/1878-0261.12743↗
- Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
Grants 1
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Luisa F. Escobar‐Hoyos · 3 shared papers, 2020–2022 · strength 0.46
- Paper Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. DOI 10.18632/oncotarget.27901↗
- Paper Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases DOI 10.1101/2022.08.27.504988↗
- Paper An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subt… DOI 10.1002/1878-0261.12743↗
- Luke A. Torre-Healy · 2 shared papers, 2022–2023 · strength 0.33
- Naim U. Rashid · 2 shared papers, 2020–2023 · strength 0.27
- Paper Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-sub… DOI 10.1038/s42003-023-04461-6↗
- Paper Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in P… DOI 10.1158/1078-0432.ccr-19-1467↗
- Richard A. Moffitt · 2 shared papers, 2020–2023 · strength 0.27
- Paper Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-sub… DOI 10.1038/s42003-023-04461-6↗
- Paper Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in P… DOI 10.1158/1078-0432.ccr-19-1467↗
- Jen Jen Yeh · 2 shared papers, 2020–2023 · strength 0.27
- Paper Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-sub… DOI 10.1038/s42003-023-04461-6↗
- Paper Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in P… DOI 10.1158/1078-0432.ccr-19-1467↗
- Chun‐Hao Pan · 2 shared papers, 2020–2022 · strength 0.24
- Kenneth Reed Shroyer · 2 shared papers, 2020–2022 · strength 0.24
- Steven D Leach · 1 shared paper, 2021 · strength 0.22
- Andrew J. Aguirre · 1 shared paper, 2023 · strength 0.18
- Ki Oh · 1 shared paper, 2023 · strength 0.18
- Lucia Roa‐Peña · 1 shared paper, 2022 · strength 0.14
- Timothy Spicer · 1 shared paper, 2020 · strength 0.09
- David Kuang-Fu Chang · 1 shared paper, 2020 · strength 0.09
- Andrew Victor Biankin · 1 shared paper, 2020 · strength 0.09
- David C. Linehan · 1 shared paper, 2020 · strength 0.09
- Timothy M. Nywening · 1 shared paper, 2020 · strength 0.09
- Roheena Z. Panni · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.